Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (298)	9/3/2002 9:26:29 AM
From: Michael Young	Read Replies (1) \| Respond to of 508

Good article. Although he probably should have pointed out that there was a strong survival trend in the entire trial population, even if it missed statistical significance. MIKE

To: rkrw who wrote (298)	9/3/2002 10:10:08 AM
From: IRWIN JAMES FRANKEL	Read Replies (1) \| Respond to of 508

Note this contrast: "Strieter has no financial ties to Intermune and doesn't own its stock." ... "Strieter is in charge of another Actimmune study that strives to understand how the drug really works. Results are expected by the end of the year." :-) ij